Similarly, the AML1-ETO oncogenic fusion protein identified in t(8;21) AML (acute myeloid leukemia) patients has the capacity to recruit the HDAC1, 2 and/or 3 family members, thereby repressing AML1 target gene expression, which ultimately results in the prevention of myeloid differentiation and induction of cellular transformation [42,66,132,133,134,135,136,137,138,139]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.